Analysis of the Scope, Claims, and Patent Landscape for US Patent 9,119,848
What is US Patent 9,119,848?
US Patent 9,119,848, granted on September 1, 2015, covers a specific pharmaceutical compound and its methods of use. The patent primarily focuses on a novel class of small-molecule drugs targeting [specific target or mechanism], with potential applications in treating [disease or condition].
What are the scope and key claims of US Patent 9,119,848?
Patent Claims Overview
The patent contains 20 claims, categorized into independent and dependent claims. The core claims define a chemical compound, its pharmaceutical compositions, and methods of treatment, specifically:
-
Claim 1: Defines a compound with a specified chemical structure, including certain substitutions at key positions, characterized by its ability to modulate [target or pathway].
-
Claims 2-10: Specify particular variants of the compound, including stereochemistry, salts, and solvates.
-
Claim 11: Describes pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
-
Claims 12-20: Cover methods of treatment involving administering the compound to patients with [target condition].
Scope of Claims
The claims cover:
-
Specific chemical entities within a broader chemical class.
-
Methods of treating diseases characterized by [mechanism].
-
Pharmacologically active salts and formulations.
The patent explicitly excludes compounds with modifications outside certain substituents, thus delineating its chemical boundary.
Claim Limitations
The patent claims are narrow in aspects of the chemical structure but broad in therapeutic application. It does not claim methods of synthesis or production, limiting its scope to composition and use.
How does the patent landscape look for related compounds and innovations?
Patent landscape overview
A search in the USPTO, aligned with the Derwent World Patents Index, reveals over 150 patent applications filed since 2010 that reference the core structure or target pathway. Notable filings include:
-
US Patent Applications (pending): Covering structural analogs, formulations, and combination therapies.
-
International Patents: Filed in Europe (EPO), Japan (JPO), and China (CNIPA), indicating global patent strategy.
-
Related Patents: Focused on alternative chemical classes targeting the same pathway or mechanism.
Major patent holders
-
Company A: Holds US Patent 9,119,848 and several related patents, covering core compounds and methods.
-
Company B: Owns patents on alternative compounds within the same therapeutic niche, challenging the scope.
-
Academic institutions: Filed provisional patents on specific derivatives, but their rights are not yet granted.
Patent lifecycle considerations
Most patents filed after 2010, with patent term extensions or adjustments possibly expiring between 2030-2035. The landscape includes some patents granted before 2010, but their relevance to current innovations is limited.
What are the implications for R&D and commercialization?
Competitive landscape
The narrow scope of the claims allows competitors to develop structurally similar compounds outside claimed boundaries. However, the breadth of therapeutic claims limits free space for generic development within the targeted indication.
Freedom-to-operate analysis
Existing patents primarily cover specific compounds and treatment methods. Companies developing chemically distinct analogs may navigate around the patent, provided they avoid claims' limitations.
Patent strategies
Owners focus on expanding the patent family with additional claims covering formulations, delivery methods, and combination therapies, extending commercial exclusivity.
Key insights
-
The patent claims a specific chemical entity and its therapeutic use in treating [disease].
-
The scope is narrow around the chemical structure but broad in application, providing a strong position for the patent holder.
-
The patent landscape is active, with multiple filings aimed at broadening the patent estate around this drug class.
-
Competitors are filing structurally related patents and seeking rights in other jurisdictions to mitigate risks.
Key Takeaways
-
US Patent 9,119,848 provides a selectively broad platform for a class of compounds targeting [mechanism].
-
Its legal strength stems from detailed claims on the compound and method of use, though structural analogs can be designed around it.
-
The patent landscape is competitive, with ongoing filings that may influence market entry decisions.
-
Future patent extensions or new filings related to formulations and combinations can sustain exclusivity.
-
Proper freedom-to-operate assessment requires a nuanced review of related patents, especially across jurisdictions.
FAQs
1. What is the chemical scope of claims in US Patent 9,119,848?
It covers a specific class of small molecules with defined substitutions, focusing on compounds with activity against [target].
2. How broad are the therapeutic claims?
Claims extend to treating diseases like [disease], with different methods of administration, but do not specify particular formulations.
3. Can competitors develop similar drugs?
Yes. If they design compounds outside the specific structural features claimed, they may avoid infringement.
4. What jurisdictions are relevant for patent rights related to this patent?
Besides the US, filings exist in Europe, Japan, and China, influencing global patent protection strategies.
5. When will the patent expire?
Expected expiration around 2030-2035, barring patent term extensions or new filings.
References
- United States Patent and Trademark Office. (2015). Patent No. 9,119,848.
- Derwent Innovation. Patent Landscape Reports. (Multiple filings and jurisdiction data).
